At 12.09 am, Sun Pharma shares were trading 3.80 per cent up at Rs 754.55. The scrip opened at Rs 725.90 and touched a high and low of Rs 773 and Rs 722, respectively. (Reuters)
Sun Pharma shares gained as much as 6.34 per cent intraday on Friday after one of its subsidiaries has received USFDA approval to manufacture and market generic version of Novartis’ Gleevec, used in treatment of cancer, in America.
At 12.09 am, shares of the company were trading 3.80 per cent up at Rs 754.55. The scrip opened at Rs 725.90 and touched a high and low of Rs 773 and Rs 722, respectively.
In a BSE filing, Sun Pharmaceutical Industries said: “One of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec, Imatinib Mesylate tablets.”
“The approval has been granted for Imatinib Mesylate tablets of 100 mg and 400 mg strengths. Imatinib Mesylate tablets, 100 mg and 400 mg are therapeutic equivalents of Novartis’ Gleevec tablets,” it added.
So far, around 7.17 lakh shares of Sun Pharma exchanged hands on the BSE as compared with two-week average daily volume of 3.68 lakh shares.
| Subscribe To Our Free Newsletter |
